Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines.

Christine E SimmonsDaniel RaysonAnil Abraham JoyJan-Willem HenningJulie LemieuxHeather McArthurPaul B CardRebecca DentChristine Brezden-Masley

Published in: Therapeutic advances in medical oncology (2022)

Tucatinib plus trastuzumab and capecitabine significantly prolongs OS, and promising preliminary response outcomes for trastuzumab-deruxtecan suggest that sequencing of these regimens following second-line therapy is reasonable.

Keyphrases

metastatic breast cancer
epidermal growth factor receptor
single cell
current status
phase ii study
locally advanced
clinical trial
stem cells
type diabetes
adipose tissue
squamous cell carcinoma
young adults
phase iii
radiation therapy
metabolic syndrome
insulin resistance
cell therapy